<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="712">
  <stage>Registered</stage>
  <submitdate>9/09/2005</submitdate>
  <approvaldate>9/09/2005</approvaldate>
  <nctid>NCT00157183</nctid>
  <trial_identification>
    <studytitle>Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation</studytitle>
    <scientifictitle>Non-invasive Ventilation and Oxygen Therapy in Cystic Fibrosis Patients With Nocturnal Oxygen Desaturation</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>35/03</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Cystic Fibrosis</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Connective tissue diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Other inflammatory or immune system disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Human Genetics and Inherited Disorders</conditioncode1>
      <conditioncode2>Cystic fibrosis</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: devices - Nocturnal oxygen , nocturnal bi-level positive pressure ventilation

Treatment: devices: Nocturnal oxygen , nocturnal bi-level positive pressure ventilation


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: devices</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Quality of life questionnaires:</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CFQoL questionnaire (Gee,Thorax,2000)(a priori chest, physical function, treatment, emotion domains)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Epworth Sleepiness Scale</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pittsburgh Sleep Quality Index</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>CF Subjective Symptoms Sleep disturbance Questionnaire (CSQ-in house)</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Medical Research Council Dyspnea Scale</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Baseline Dyspnea Index, Transitional Dyspnea Index</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Work or Study status</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Physiological:</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Nocturnal SpO2, nocturnal rise in transcutaneous CO2</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Daytime arterial blood gases (PaCO2, PaO2)</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Admission rate</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Lung function tests (FEV1, FVC, RV/ TLC)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Modified CF shuttle walk test</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Neurocognitive testing (psychomotor vigilance task, Stroop, Controlled Oral Word Association Test, Trails A and B, digit recall forwards backwards)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>PSG (sleep efficiency, arousal index, % REM sleep, urinary catecholamines)</outcome>
      <timepoint />
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Serum cytokines (IL-6, TNF alpha, IL-1 beta)</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>proven diagnosis cystic fibrosis, age 18 years or older, FEV1&lt; 70% predicted normal,
        clinically stable (no admission or antibiotics last 2 weeks, OR end of admission where
        further clinical improvement not expected), nocturnal respiratory failure (SpO2&lt;90% for &gt;
        10% of night or rise in PtcCO2 &gt; 5 mmHg in REM), daytime hypercapnia (PaCO2&gt; 45 mmHg)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Previous home O2 or NIV use, Sedative medications, Cardiac/renal/endocrine/neurological
        disease likely to compromise ventilatory control</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Crossover</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1/Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/03/2003</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>59</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/03/2006</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>VIC</recruitmentstate>
    <hospital>The Alfred - Melbourne</hospital>
    <postcode>3181 - Melbourne</postcode>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Bayside Health</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>National Health and Medical Research Council, Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Monash University</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Cystic Fibrosis Federation Australia</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The purpose of this study is to determine whether correction of low nighttime oxygen (O2)
      levels and/ or high carbon dioxide levels in patients with cystic fibrosis improves their
      quality of life. The treatments being used overnight are (1)O2 (2)pressurised air which
      assists breathing (non-invasive positive pressure ventilation, NIPPV)</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00157183</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Matthew T Naughton, MD</name>
      <address>The Alfred</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>